Teleflex (NYSE:TFX) versus Valeritas (OTCMKTS:VLRXQ) Financial Survey

Teleflex (NYSE:TFXGet Free Report) and Valeritas (OTCMKTS:VLRXQGet Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, dividends, analyst recommendations and valuation.

Analyst Ratings

This is a breakdown of current ratings for Teleflex and Valeritas, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teleflex 0 4 6 0 2.60
Valeritas 0 0 0 0 N/A

Teleflex currently has a consensus price target of $269.30, suggesting a potential upside of 9.59%. Given Teleflex’s higher possible upside, research analysts clearly believe Teleflex is more favorable than Valeritas.

Valuation & Earnings

This table compares Teleflex and Valeritas’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Teleflex $2.79 billion 4.14 $363.14 million $8.53 28.81
Valeritas N/A N/A N/A N/A N/A

Teleflex has higher revenue and earnings than Valeritas.

Institutional & Insider Ownership

97.2% of Teleflex shares are held by institutional investors. 1.4% of Teleflex shares are held by insiders. Comparatively, 1.0% of Valeritas shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Teleflex and Valeritas’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Teleflex 13.65% 15.52% 9.16%
Valeritas N/A N/A N/A

Summary

Teleflex beats Valeritas on 8 of the 8 factors compared between the two stocks.

About Teleflex

(Get Free Report)

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

About Valeritas

(Get Free Report)

Valeritas Holdings, Inc., a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey.

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.